Dassault Systèmes agreed to buy Arisglobal for up to $2 billion, aiming to build a unified AI intelligence platform across life-sciences workflows. The deal combines Arisglobal’s regulatory and safety intelligence capabilities with Dassault’s modeling and simulation footprint, targeting fragmented datasets across R&D and real-world evidence practices. For biotech and pharma stakeholders, the acquisition signals continued platform consolidation around structured knowledge graphs, pharmacovigilance intelligence, and regulatory decision support—areas where companies increasingly rely on software to manage complexity across clinical and post-market stages. The transaction also highlights competition for “enterprise life-sciences” toolchains where modeling and evidence synthesis platforms attempt to connect virtual and real-world outputs.